Home

The Korea Herald

Latest news

Most Popular

  1. 1

    Opposition head pleads for support in ‘fight against Yoon dictatorship’

    Opposition head pleads for support in ‘fight against Yoon dictatorship’
  2. 2

    Koreans prefer cash in Chuseok gifting for parents

    Koreans prefer cash in Chuseok gifting for parents
  3. 3

    Apple to launch iPhone15 series in S. Korea on Oct. 13

    Apple to launch iPhone15 series in S. Korea on Oct. 13
  4. 4

    Xi says he will consider S. Korea visit

    Xi says he will consider S. Korea visit
  5. 5

    S. Korea, US conduct underwater search operation for downed jet, Korean War remains

    S. Korea, US conduct underwater search operation for downed jet, Korean War remains
  6. 6

    BTS' Suga begins military service

    BTS' Suga begins military service
  7. 7

    Opposition party leader ends 24-day hunger strike for treatment

    Opposition party leader ends 24-day hunger strike for treatment
  8. 8

    Surveillance cameras to be a must in hospital operating rooms

    Surveillance cameras to be a must in hospital operating rooms
  9. 9

    US finalizes national security 'guardrails' for CHIPS funding

    US finalizes national security 'guardrails' for CHIPS funding
  10. 10

    Ministry uncovers 1,802 Youth Protection Act violations

    Ministry uncovers 1,802 Youth Protection Act violations
피터빈트

Samsung Bioepis seeks approval for Humira biosimilar in Korea

By 이지윤

Published : Sept. 26, 2016 - 15:02

    • Link copied

[THE INVESTOR] Samsung Bioepis is seeking regulatory approval to sell its biosimilar drug referencing AbbVie’s top-selling rheumatoid drug Humira in South Korea.

According to industry sources on Sept. 26, the biopharma development unit of Samsung Group has recently submitted its application to the Korean authorities for the sales approval of its Humira biosimilar, called SB5.

Sources said the final approval could be granted in the first half of next year. 


A researcher works at a lab of Samsung Bioepis. A researcher works at a lab of Samsung Bioepis.


Humira, together with Enbrel and Remicade, are considered the top-selling biotech drugs that block chemicals linked to inflammation.

Samsung Bioepis is already selling its own biosimilar versions of Enbrel and Remicade in South Korea and Europe.

Adding to the three drugs, the company is also waiting for the approval for its SB3, a biosimilar for Roche’s breast cancer drug Herceptin, in South Korea.

By Lee Ji-yoon (jylee@heraldcorp.com)

More from Headlines